Combination therapy(toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer:A case report
作者机构：Department of Dermatologythe Second Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Dermatologythe Second Clinical Medical College of Guangzhou University of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic DiseasesGuangzhou 510120Guangdong ProvinceChina
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2022年第10卷第11期
页 面：3478-3484页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases No. 2018B030322012
主 题：Toxic epidermal necrolysis Toripalimab Lenvatinib Programmed cell death-1 inhibitor Liver cancer Case report
摘 要：BACKGROUND Both programmed cell death-1(PD-1)inhibitors and lenvatinib,which have a synergistic effect,are promising drugs for tumor *** is generally believed that combination therapy with a PD-1 inhibitor and lenvatinib is safe and ***,we report a case of toxic epidermal necrolysis(TEN),a grade 4 toxicity,after this combination *** SUMMARY A 39-year-old male presented with erythema,blisters and erosions on the face,neck,trunk and limbs 1 wk after receiving combination therapy with lenvatinib and toripalimab,a PD-1 *** skin injury covered more than 70%of the body surface *** was previously diagnosed with liver cancer with cervical vertebra ***,prominent necrotic keratinocytes,hyperkeratosis,liquefaction of basal cells and acantholytic bullae were observed in the *** vessels in the dermis were infiltrated by lymphocytes and *** immunofluorescence staining was ***,the diagnosis was confirmed to be TEN(associated with combination therapy with toripalimab and lenvatinib).Full-dose and long-term corticosteroids,high-dose intravenous immunoglobulin and targeted antibiotic drugs were *** rashes gradually faded;however,as expected,the tumor ***, sorafenib and regorafenib were given in succession, and the patient was still alive at the10-mo *** attention should be given to rashes that develop after combination therapy with PD-1inhibitors and lenvatinib. Large-dose and long-course glucocorticoids may be crucial for thetreatment of TEN associated with this combination treatment.
维普期刊数据库